CJC-1295 ipamorelin for women is not a female-specific treatment, and no clinical trial has tested the combination in women. Separate studies show that each component can change growth-hormone signaling, but they do not establish improvements in menopause symptoms, sleep or body composition. For a woman in perimenopause or after menopause, the useful question is not whether the blend is marketed to women. It is whether her symptoms fit the growth-hormone axis, whether estrogen route changes the lab picture, and whether the limited evidence justifies a monitored prescription.
What CJC-1295 ipamorelin for women means
CJC-1295 and ipamorelin reach the same pituitary system through different receptors. CJC-1295 is an analogue of growth-hormone-releasing hormone, while ipamorelin acts at the ghrelin receptor. Neither supplies growth hormone directly. The rationale for pairing them is that two upstream signals may prompt a pituitary response while the body's feedback loops remain involved. The broader CJC-1295 and ipamorelin explainer owns that mechanism in detail.
The formulation matters. The best-known human CJC-1295 studies used the long-acting form with a drug affinity complex, or DAC. Promise's blend uses a short-acting form without DAC. Results about how long the DAC form elevated hormone levels cannot simply be carried over to a no-DAC blend.
What the component studies actually show
The direct human record answers pharmacology questions, not the outcome questions most women arrive with.
| Evidence | Who and what was studied | What it can support | What it cannot support |
|---|---|---|---|
| CJC-1295, JCEM 2006 | Healthy adults ages 21–61 received long-acting CJC-1295 with DAC | Mean GH rose 2- to 10-fold for at least 6 days and mean IGF-1 rose 1.5- to 3-fold for 9–11 days after one injection | Female-specific results, no-DAC kinetics, sleep or body-composition outcomes |
| Ipamorelin, Pharmaceutical Research 1999 | Eight healthy men at each of five intravenous dose levels | A single GH-release episode peaked at about 0.67 hours; terminal half-life was about 2 hours | Results in women, subcutaneous use, menopause symptoms or long-term outcomes |
| CJC-1295 plus ipamorelin | No published clinical trial of the combination was identified | A mechanism-based reason to study the pair | A clinical effect estimate for women, with or without menopause |
The Teichman CJC-1295 trial and the Gobburu ipamorelin study establish that the individual molecules can move GH-axis markers under their study conditions. They do not show that the marketed combination improves sleep, reduces fat or adds lean mass in women. That distinction is the center of the evidence, not a footnote.
Perimenopause changes the background, not the evidence
Growth-hormone output generally becomes lower and less orderly with age, while changing ovarian hormones can further alter the GH–IGF-1 axis. At the same time, sleep disruption and body-composition change become more common around the menopause transition. Those overlaps explain why women ask about secretagogues, but they do not prove that low GH caused a particular symptom.
The longitudinal SWAN analysis followed women through their final menstrual period and found that the rate of fat gain doubled at the start of the transition while lean mass began to decline; those trajectories leveled off about two years after the final menstrual period (Greendale et al., JCI Insight 2019). This describes menopause-associated change. It was not a peptide-treatment study.
Sleep is similarly easy to overread. A laboratory study found that the timing relationship between the first nighttime GH peak and slow-wave sleep was weaker after menopause (Kalleinen et al., Sleep Medicine 2012). That does not show that raising GH markers restores sleep. Hot flashes, sleep apnea, mood, medications and thyroid disease can all produce a similar complaint and may need their own evaluation.
Oral estrogen can change the IGF-1 reading
Estrogen therapy is not a simple yes-or-no variable for this axis. Route matters because oral estrogen reaches the liver first and can suppress hepatic IGF-1 production. In a randomized crossover study of nine healthy postmenopausal women, oral estradiol lowered baseline and GH-stimulated IGF-1; low-dose transdermal estradiol did not alter baseline or peak IGF-1 (Lissett and Shalet, JCEM 2003).
That does not make one menopause-therapy route universally better. It means an IGF-1 result cannot be interpreted cleanly without knowing the estrogen product, route, dose and timing. A provider may also need to separate a medication effect on the lab from evidence of impaired pituitary function. Hormone therapy should not be changed merely to make an IGF-1 number move.
Body composition and sleep claims outrun the data
No trial has measured whether this combination changes fat mass, lean mass, strength or sleep in women. A shift in GH or IGF-1 is an intermediate marker, not proof of a visible or felt outcome. The SWAN findings make body-composition concerns understandable, but they do not turn this blend into a menopause treatment or a weight-loss medication.
Sermorelin is a related, single-pathway GHRH analogue. The small female studies discussed in sermorelin for women are not evidence for CJC-1295 with ipamorelin, but they show why sex-specific interpretation matters: biochemical response and clinical benefit are separate endpoints. There is no female head-to-head trial showing that either approach is better.
Tolerability is also part of the decision, especially when benefit is uncertain. Ipamorelin side effects covers the available safety record and its limits rather than folding a long adverse-effect list into this article.
How a provider frames the decision
A useful review starts with the goal and competing explanations, then asks whether the expected signal can be measured. Typical considerations include age-adjusted IGF-1, glucose status, thyroid and pituitary history, current estrogen therapy, medications, cancer history and symptoms that may point to a different cause. Pregnancy and breastfeeding are exclusions because reproductive and infant-exposure safety have not been established for the combination.
The prescribed amount and follow-up plan are individualized. CJC-1295 ipamorelin dosing explains how clinicians weigh formulation, labs and response without turning a published protocol into self-dosing instructions.
Promise dispenses CJC-1295 with ipamorelin as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The FDA explains that compounded drugs do not undergo its premarket review for safety, effectiveness or quality. Regulatory status is one input rather than a marketing verdict: a licensed provider may still prescribe a compounded formulation when medically appropriate, and that decision is between the patient and the doctor.
A sound plan has a measurable question
A clear goal might involve symptoms, a baseline lab or another finding that can be reassessed. A vague promise of better sleep, easier fat loss and faster recovery cannot tell patient or provider whether the treatment earned its place. Follow-up should be willing to confirm, adjust or stop the plan rather than reinterpret every outcome as success.
At Promise, a licensed provider reviews every request and prescribes or declines on medical eligibility; not everyone qualifies. That accountability matters most when the combination has no female-specific clinical trial and estrogen can change the very marker used to follow it.